ACTAVIS LABORATORIES
LIVE

Serial Number

79130027

Owner

Actavis Group PTC ehf

Attorney

GABRIELLE S. ROTH

Filing Date

Nov 21, 2012

Add to watchlist:

No watchlists yet
View on USPTO

ACTAVIS LABORATORIES Trademark

Serial Number: 79130027 • Registration: 4686257

ACTAVIS LABORATORIES is a trademark filed by Actavis Group PTC ehf on November 21, 2012. The trademark is classified under Class 1 (Chemicals), Class 3 (Cosmetics & Cleaning), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Actavis Group PTC ehf (50 trademarks)

Dalshraun 1

Entity Type: 78

Trademark Details

Filing Date

November 21, 2012

Registration Date

February 17, 2015

Published for Opposition

March 11, 2014

Cancellation Date

November 21, 2022

Goods & Services

Pharmaceutical preparations for the prevention and treatment of alimentary tract and metabolic diseases and disorders, dermatological diseases and disorders, genito-urinary and sexual diseases and disorders, musculo-skeletal system diseases and disorders, nervous system diseases and disorders, respiratory system diseases and disorders, cardio-vascular diseases and disorders specifically excluding tissue plasminogen activators; pharmaceutical preparations for the prevention and treatment of sensory organ diseases and disorders, systemic hormonal pharmaceutical preparations and substances, pharmaceuticals, namely, anti-infectives, pharmaceutical preparations, namely, antineoplastic and immunomodulating agents, antiparasitic preparations and substances; oral contraceptives; contraceptive preparations; hormone replacement therapy preparations; pharmaceutical preparations for the prevention of preterm birth or pregnancy; pharmaceutical preparations for the treatment and prevention of urinary incontinence and overactive bladder; pharmaceutical preparations for the treatment and prevention of iron deficiency and anemia; pharmaceutical preparations for the treatment and prevention of osteoporosis; pharmaceutical preparations for the treatment and prevention of endometriosis; pharmaceutical preparations for the treatment and prevention of symptoms associated with uterine fibroids; iron chelating pharmaceutical preparations; fertility enhancing preparations; pharmaceutical preparations and substances for the treatment of premenstrual syndrome, post natal depression, fluctuating hormone levels; pharmaceutical preparations and substances for infertility disorders, pharmaceutical preparations and substances for in vitro fertilization (ivf); pharmaceutical preparations in the nature of medicated dental rinses, mouth rinses, mouthwashes, dental lozenges, dental tablets and medicated chewing gum for the treatment or prevention of halitosis, cavities, gingivitis, plaque, and dry mouth; dental wax; pharmaceutical preparations in the nature of pregnancy test kits, ovulation test kits and in-vitro ovulation prediction test kits all for home use; pharmaceutical preparations in the nature of diagnostic test kits for home use for detecting urinary tract infections, for detecting menopause, for detecting vaginal pH balances and for detecting sexually-transmitted diseases, all primarily composed of test strips, collection containers, medical diagnostic reagents and assays; pharmaceutical preparations for skin care; all the foregoing specifically excluding tissue plasminogen activators

Soaps; Perfumery; Essential Oils; Cosmetics, namely, cosmetic preparations for skin care, cosmetic preparations for body care, cosmetic preparations for bath and shower, cosmetic creams, lotions, and ointments and gels for skin care; cosmetic skin fresheners and toners; cosmetic preparations for the hair and scalp, and hair lotions; Dentifrices, namely, anti-cavity dental rinses, non-medicated mouth rinses and mouth washes, cosmetic preparations for the care of mouth and teeth

Chemicals used in industry and science, namely, active chemical ingredients for use in the manufacture of pharmaceuticals for the prevention and treatment of illnesses, diseases and disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the sensory system, and the genitourinary system, in the treatment of inflammatory disorders and diseases, and for treatment in dermatology, oncology, hematology, tissue and organ transplantation, ophthalmology and gastroenterology; and chemical additives for use in the manufacture of pharmaceuticals; chemical preparations for scientific purposes; chemical preparations for use in industry

Scientific and technological services, namely, consulting in the field of pharmaceuticals pertaining to biotechnology, product evaluation, diagnostics, testing and inspection; pharmaceutical research and development; industrial analysis and research services in the field of pharmaceuticals and chemical analysis

Filing History

NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG E-MAILED
Jun 17, 2023 DENC
DEATH OF INTERNATIONAL REGISTRATION
Jun 17, 2023 DETH
NEW REPRESENTATIVE AT IB RECEIVED
Oct 22, 2022 NREP
TOTAL INVALIDATION PROCESSED BY THE IB
Aug 22, 2022 INNT
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
Aug 2, 2022 INTS
INVALIDATION PROCESSED
Aug 2, 2022 INPC
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
May 3, 2022 INTR
CANCELLED SECTION 71
Sep 3, 2021 C71T
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Feb 17, 2020 REM3
FINAL DECISION TRANSACTION PROCESSED BY IB
Jul 17, 2015 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 1, 2015 FICS
FINAL DISPOSITION PROCESSED
Jul 1, 2015 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
May 17, 2015 FICR
REGISTERED-PRINCIPAL REGISTER
Feb 17, 2015 R.PR
TTAB RELEASE CASE TO TRADEMARKS
Jan 14, 2015 TMBN
OPPOSITION TERMINATED NO. 999999
Jan 14, 2015 OP.T
OPPOSITION DISMISSED NO. 999999
Jan 14, 2015 OP.D
REFUSAL PROCESSED BY IB
Oct 3, 2014 RFNP
OPPOSITION INSTITUTED NO. 999999
Sep 4, 2014 OP.I
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
Sep 3, 2014 OPNS
OPPOSITION NOTICE (IB REFUSAL) CREATED
Sep 3, 2014 OPNC
EXTENSION OF TIME TO OPPOSE RECEIVED
Mar 24, 2014 ETOF
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Mar 11, 2014 NPUB
PUBLISHED FOR OPPOSITION
Mar 11, 2014 PUBO
NOTIFICATION PROCESSED BY IB
Mar 7, 2014 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Feb 19, 2014 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Feb 19, 2014 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Feb 19, 2014 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Feb 4, 2014 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Feb 4, 2014 CNSA
EXAMINER'S AMENDMENT ENTERED
Feb 4, 2014 XAEC
ASSIGNED TO LIE
Feb 4, 2014 ALIE
EXAMINER'S AMENDMENT ENTERED
Feb 4, 2014 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Feb 3, 2014 GNEN
EXAMINERS AMENDMENT E-MAILED
Feb 3, 2014 GNEA
EXAMINERS AMENDMENT -WRITTEN
Feb 3, 2014 CNEA
NOTIFICATION OF FINAL REFUSAL EMAILED
Aug 28, 2013 GNFN
FINAL REFUSAL E-MAILED
Aug 28, 2013 GNFR
FINAL REFUSAL WRITTEN
Aug 28, 2013 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Jul 25, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jul 24, 2013 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jul 24, 2013 TROA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jul 16, 2013 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jul 16, 2013 REAP
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
Jul 9, 2013 CREV
CORRECTION TRANSACTION RECEIVED FROM IB
Jul 6, 2013 CRCV
REFUSAL PROCESSED BY IB
Jul 1, 2013 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 7, 2013 RFCS
REFUSAL PROCESSED BY MPU
Jun 7, 2013 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 7, 2013 RFCR
NON-FINAL ACTION WRITTEN
Jun 6, 2013 CNRT
APPLICATION FILING RECEIPT MAILED
Jun 4, 2013 MAFR
ASSIGNED TO EXAMINER
May 31, 2013 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 31, 2013 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 30, 2013 REPR